Newcastle Clinical Trials Unit


Fairpark II

Conservative iron chelation as a disease-modifying strategy in Parkinson’s disease

  • Study stage: Closed
  • Sponsor: Lille University
  • Funder: European Commission Horizon 2020 Grant
  • Therapeutic area: Neurological
  • Type of study: CTIMP

Aim: To demonstrate for the first time in a large phase II, randomised, placebo-controlled trial that conservative iron chelation, with the prototype drug Deferiprone, will slow down the progression of symptoms in Parkinson's disease patients and will not be associated with a clinically negative benefit / risk ratio.

Primary outcome:

The change in the total MDS-UPDRS score between baseline and 36 weeks (i.e. the end of the placebo-controlled phase for analysis of both disease modifying and symptomatic effects).

  • Population: Adult
  • Phase: IIb
  • Design: RCT
  • Setting: Secondary care
  • Planned Sample Size: 322